Kornimate/medical-research-clean huggingface dataset:
low back pain and depression: cohort study

Conditions: Low Back Pain; Pelvic Pain; Depression

Summary: the aims of this study are to investigate whether pelvic pain and low back pain disability are associated with postpartum depression and to compare the prevalence between women without low back pain and disability and women with low back pain (lbp) and disability every trimester, and correlate postpartum depression and some clinical and biopsychosocial variables: subgroups of lbp, disability, pain intensity, pain widespread and nationality, in a cohort of spanish women at 2 months postpartum.

295 pregnant women will formed the cohort, during all pregnancy and two months after delivery. the edinburgh postnatal depression scale was used to evaluate depressive symptoms at 2 months postpartum. the lbp will be evaluated based on self-administrated questionnaire, and the patients with lbp will be classified in to lumbopelvic groups according to mechanical assessment of the lumbar spine, pelvic pain provocation tests, standard history, pain intensity on visual analogue scale, spread of pain through pain drawings and oswestry index was used to evaluated the disability. logistics regression analysis will performed to explain the predictors of depression.

Eligibility criteria:
inclusion criteria: * inclusion criteria were being pregnant between for 12 weeks to 16 weeks, * with an expected normal pregnancy (as determined by midwife), * being able to understand and read spanish. exclusion criteria: * exclusion criteria were end of pregnancy before gestational weeks 37 (delivery or abortion), * serious intellectual impairment, * having had a systemic disease (spondylitis, infectious, vascular, metabolic or endocrine related process), rheumatic disease, fibromyalgia, lumbopelvic pain or * verified diagnosis of spinal problems in the previous 6 months, or * a history of fracture, neoplasm or previous spinal, pelvic or femur surgery. * another exclusion criterion was a diagnosis of depression or anxiety in the previous year.

Keywords: low back pain oswestry questionnaire post-partum depression pelvic pain
weukbre5716: steroid-related damage in systemic lupus erythematosus (hopkins)

Conditions: Systemic Lupus Erythematosus

Summary: the study is designed to assess the association between steroid exposure and five potentially steroid-related adverse events within a cohort of individuals with systemic lupus erythematosus (sle). study objectives are to quantify the fraction of the risk of new (i) diabetes, (ii) hypertension, (iii) cataracts, (iv) osteoporosis and (v) avascular necrosis that is attributable to cumulative corticosteroid exposure in sle patients. the study will consist of five matched case-control analyses nested within the hopkins lupus cohort. cases will be incident sle cases who have developed one of the case outcomes (diabetes, hypertension, cataracts, osteoporosis with fracture or vertebral collapse or avascular necrosis). controls will be matched to cases on time since sle diagnosis. the primary exposures to be assessed are cumulative dose of steroid (g) and cumulative duration of exposure to steroids. the extent of the risk associated with steroids will be explored through modeling of the relationship and through calculation of attributable risks of exposure (number of cases associated with the highest exposure quartile of each primary exposure).


Eligibility criteria:
inclusion criteria: * newly diagnosed sle as per acr criteria * no history of "case" event of interest in follow-up time prior to sle diagnosis (case) or during follow-up time since sle diagnosis that is equivalent to length of case at-risk time period (controls) exclusion criteria: * none

Keywords: hypertension avascular necrosis systemic lupus erythematosus osteoporosis steroid diabetes cataracts
ons in gastric cancer after total gastrectomy

Conditions: Gastric Cancer

Summary: gastric cancer patients after total gastrectomy will be randomized to oral nutritional supplement group or control group at discharge. patients will receive 6 months of oral nutritional supplement or normal diet after discharge. the primary and secondary outcomes will be collected.

gastric cancer patients after total gastrectomy at discharge, if she/he has nutrition risk (nrs2002≥3), then she/he will be randomized to oral nutritional supplement (ons) group or control (c) group after discharge. in the ons group, in addition to diet, and patients will also consume enteral nutritional powder (500ml/d，500kcal/d) lasted for 6 months. in the c group, patients will receive normal diet. both groups will receive nutrition counseling. the primary and secondary outcomes will be collected.

Eligibility criteria:
inclusion criteria: 1. informed consent of patients or their legal representatives to participate in this study 2. consecutive adult (18-80 years) patients underwent radical gastrectomy (total gastrectomy) 3. nutrition risk screening (nrs) 2002≥3 at discharge 4. eastern cooperative oncology group (ecog) score of 0-2 at discharge 5. normal liver and kidney function exclusion criteria: 1. unable to oral or consume ons 2. allergy to any ingredient in the oral nutrition powder 3. pregnancy 4. palliative surgery or gastric stump cancer 5. congenital acquired immune deficiency disease 6. severe liver and kidney diseases including active hepatitis, cirrhosis, and uremia diabetes has developed complications or uncontrolled by medications 7. motor system diseases cannot complete grip strength measurement and 5-time chair stand test 8. have cognitive impairment, unable to complete the relevant questionnaires 9. expected to require tube feeding after discharge from the hospital

Keywords: oral nutritional supplement sarcopenia long-term nutritional status
rapid ventricular pacing in surgical treatment of intracranial aneurysms

Conditions: Intracranial Aneurysm; Surgical Clip

Summary: treatment of complex unruptured intracranial aneurysms (uia) remains challenging to date. therefore, advanced techniques are required to achieve an optimal result in treating these patients safely. in this study, the safety and efficacy of rapid ventricular pacing (rvp) to facilitate microsurgical clip-reconstruction has been studied prospectively in a joined neurosurgical, anesthesiological and cardiological study.

treatment of complex unruptured intracranial aneurysms (uia) remains challenging to date. therefore, advanced techniques are required to achieve an optimal result in treating these patients safely. in this study, the safety and efficacy of rapid ventricular pacing (rvp) to facilitate microsurgical clip-reconstruction has been studied prospectively in a joined neurosurgical, anesthesiological and cardiological study. patients with complex uia were prospectively enrolled and the safety and efficacy of rvp were evaluated recording cardiovascular events and outcome of the patients as well as the amount of aneurysm occlusion after the surgical clip-reconstruction procedure.

Eligibility criteria:
inclusion criteria: * complex uia intended to be treated by microsurgical clip-reconstruction * application of rvp intra-operatively exclusion criteria: * structural heart disease or conductance abnormalities

Keywords: intracranial aneurysm surgical clipping rapid ventricular pacing
evaluation of the safety and efficacy of vardenafil in subjects with erectile dysfunction

Conditions: Erectile Dysfunction

Summary: erectile dysfunction (ed) is defined as the inability to achieve or maintain an erection sufficient for satisfactory sexual performance. an ideal treatment option should be effective and reliable, have minimal side effects, be simple to use and affordable. the aim of this study was to investigate safety, tolerability and efficacy of vardenafil following a flexible dose treatment schedule in subjects with varying aetiology.


Eligibility criteria:
inclusion criteria: * men \>/= 18 years of age, * ed 6 months or longer * stable sexual relationship for \> 6 month. exclusion criteria: * primary hypoactive sexual desire * history of myocardial infarction, stroke or life-threatening arrhythmia within prior 6 month * nitrate therapy * other exclusion criteria apply according to the summary of product characteristics

Keywords: erectile dysfunction vardenafil
efficacy and toxicity of blinatumomab in the french atu for adult bcp-all r/r, or with mrd+ (french-cyto)

Conditions: Acute Lymphoblastic Leukemia, in Relapse; Acute Lymphoblastic Leukemia With Failed Remission

Summary: the outcome of young adults (18-60 years) with all has been dramatically improved by the use of pediatric-inspired trials. about 60% of these young adult patients will be cured at 5 years. in this context, early evaluation of minimal residual disease (mrd) at complete remission has been shown to be one of the most powerful prognostic factor, but also predictive of the benefit of allogeneic stem cell transplantation (asct). despite this global improvement, about 30% of patients experience a relapse and will be exposed to be refractory to salvage therapy or to early disease escape. in adult all, the most important prognostic factors at relapse are : the time from first cr to relapse, the achievement of a second complete remission (cr), and the feasibility of asct. blinatumomab is a bispecific t-cell engager that recruits t-cell on cd19 positive blast cells and induces anti-leukemic cytotoxicity. in a phase 3 trial in relapse/refractory philadelphia-negative (ph-) all, 43% of patients achieved a cr or cr with partial hematological recovery (crh), with the majority of responses occurring within the first cycle. in patients with positive mrd (mrd+) bcp-all, blinatumomab resulted in complete mrd response in 78% of patients after one cycle. between 2012 and 2016, blinatumomab was available in france for r/r and mrd+ all adult patients through the french compassionate use program. about 92 adult all were treated at different stages of the disease in 27 centers.

to evaluate the efficacy of blinatumomab given in the french compassionate use program, in term of overall survival in both r/r (first cohort) and mrd positive (second cohort) patients. to evaluate the efficacy of blinatumomab given in the french compassionate use program, in term of cr/crh in r/r patients, to evaluate the efficacy in term of molecular response in both r/r and mrd+ cohorts, to evaluate the efficacy of blinatumomab given in the french compassionate use program, in both ph+/ph- all patients to evaluate the feasibility and the safety of blinatumomab administration in a multi-center setting.to evaluate the feasibility of allogeneic stem cell transplant after blinatumomab administration in both populations.

Eligibility criteria:
inclusion criteria: patient with philadelphia-negative or positive (ph+) all in relapse, refractory to salvage therapy, or with mrd positive all that received blinatumomab in the french atu program., * patient treated in the graall network, * patient who does'nt object to participate in the study exclusion criteria : - none
real life study of biologicals in patients with severe crswnp

Conditions: Chronic Rhinosinusitis With Nasal Polyps

Summary: this study is a pragmatic, real-life, observational study recruiting adult patients with chronic rhinosinusitis with nasal polyposis who are eligible to start biologicals as standard treatment. the aim of this study is to observe the long-term outcomes of biologicals in crswnp patients with or without comorbid asthma in 'real life'. moreover, the investigators will gain insight into the mechanisms of biologicals in the local and systemic immunity of these patients and investigate novel local and systemic biomarkers and predictors of response.

in this project, thanks to intense collaboration between the ent department and the pulmonary diseases within the allergy network uz gent, the investigators set up a prospective study and biobank with the following aims: * to observe and follow-up on clinical characteristics in patients with chronic rhinosinusitis with nasal polyposis (crswnp) with or without asthma. primary outcomes will be the endoscopic total nasal polyp score (nps) and the nasal symptom scores (snot-22, vas, ncs and upsit). * identifying key nasal inflammatory biomarkers to predict therapeutic response to biologicals in crswnp patients (identification on blood samples, nasal secretions, small tissue biopsies and superficial scrapings before, during and at month 24 of treatment). * unravel the effects of biologicals in the local nasal immune regulation. * performing additional analyses to search for new biomarkers via complete proteomic analysis. using a unique combination of nasal sampling and state of the art biomarker discovery, the investigators believe this research will provide unprecedented insights which will aid the treatment of patients with biologicals.

Eligibility criteria:
inclusion criteria: patients must meet the following criteria to be eligible for the enrolment in the study: * signed informed consent form (icf), * age between 18 and 80 years at time of signing icf, * able to comply with the study protocol, in the investigator's judgment, * in group one: patients with severe allergic and/or eosinophilic asthma, defined by being currently treated with a biological (soc) or starting treatment with a biological (soc). * in group two: patients with crswnp with or without asthma, defined by starting treatment with a biological (soc) and fulfill the criteria for reimbursement of a biological therapy exclusion criteria: patients who do not meet the reimbursement criteria of a biological therapy cannot participate in the study.
telementoring intervention (echo) for the transformation of professional engagement, practice efficiency, and community building through team meetings in diagnostic imaging clinicians

Conditions: Hematopoietic and Lymphoid Cell Neoplasm; Malignant Solid Neoplasm

Summary: this trial studies how well the extension for community healthcare outcomes (echo) telementoring intervention works in transforming professional engagement, practice efficiency, and community building through team meetings in diagnostic imaging clinicians. this study may help researchers learn more about the potential benefits of a model for team meetings aimed at bringing physicians together from multiple practice locations when few opportunities exist for meaningful, collegial interactions. it may also help diagnostic imaging clinicians engage more effectively with colleagues at distant sites and become more engaged with their work.

primary objective: i. to determine the feasibility of the proposed anti-burnout intervention for faculty at md anderson, defined as at least 35/50 of participants each attending at least 9 out of 13 sessions. secondary objectives: i. to explore any changes in burnout, measured by the maslach burnout inventory (mbi) and mini-z surveys. ii. to explore any changes in the self-reported health status of participants, as measured by the rand short-form 36 (sf36) survey. iii. to understand participants' perception of the benefits and usefulness of the intervention, measured by the customized globalized perception/impression of benefits survey. iv. to define methods for improving the intervention, based on participants' feedback following each session. outline: participants are randomized to 1 of 2 arms. arm a: participants attend echo telementoring sessions over 1 hour weekly for 13 weeks. arm b: participants are placed on a wait-list for 13 weeks and then attend echo telementoring sessions over 1 hour weekly for 13 weeks.

Eligibility criteria:
inclusion criteria: * faculty must be diagnostic imaging clinicians with a primary appointment in the division of diagnostic imaging at md anderson exclusion criteria: * faculty that have an official leadership role (division head or department chair) * faculty that have previously participated in any previous live echo clinic or echo activity
pemetrexed plus a comparator versus a combination of 2 comparators in first-line treatment of colorectal cancer

Conditions: Colorectal Cancer

Summary: in this study, patients will receive either pemetrexed plus irinotecan or 5-fluorouracil (5-fu), leucovorin, and irinotecan. the purposes of this study are to determine: * how pemetrexed plus irinotecan compares with 5-fu, leucovorin, and irinotecan in terms of efficacy. * the safety of pemetrexed plus irinotecan and any side effects that might be associated with it as compared with 5-fu, leucovorin, and irinotecan. * whether pemetrexed can help patients with colorectal cancer.


Eligibility criteria:
inclusion criteria: the patient must have: * histologic or cytologic diagnosis of adenocarcinoma of the colon or rectum. * performance status of 0 to 2 on the ecog performance status scale. * standard postoperative adjuvant radiation therapy for rectal cancer is allowed. * locally advanced or metastatic disease. * must be 18 years of age. exclusion criteria: the patient must not have: * received prior chemotherapy for advanced disease. prior adjuvant therapy, including 5-fu, is allowed if it has been more than 12 months since the last treatment. * received prior treatment with irinotecan in the adjuvant setting. * are unable to take vitamin b12 or folic acid. * are unable to interrupt aspirin, other nonsteroidal anti-inflammatory drugs, or cox-2 inhibitors for a 5-day period. * have a second primary malignancy except carcinoma in situ of the cervix or nonmelanomatous skin cancer, unless that prior malignancy was diagnosed and definitively treated at least 5 years previously with no subsequent evidence of recurrence.
a registry to evaluate the flexitouch system and flexitouch plus for treatment of head and neck lymphedema

Conditions: Head and Neck Lymphedema

Summary: the objective of this registry is to evaluate the long term effectiveness of the flexitouch system and flexitouch plus in those with head and neck lymphedema. this outcome data will include information regarding each subject's medical history, symptoms, quality of life, pain, range of motion (rom), swelling, ease of use, treatment satisfaction, treatment compliance, and adverse events.


Eligibility criteria:
inclusion criteria: * age ≥ 18 years * a diagnosis of head and/or neck lymphedema * must be able and willing to participate in all aspects of the registry and provide informed consent prior to registry participation * head and chest measurements within the following: * crown of head circumference: ≤ 72 cm * chest circumference: ≤ 158 cm * prescribed the flexitouch system or flexitouch plus exclusion criteria: * uncontrolled hyperthyroidism or parathyroidism (for which endocrinologist recommends against neck compression) * carotid sinus hypersensitivity syndrome * symptomatic carotid artery disease, as manifested by a recent transient ischemic attack (within 30 days), ischemic stroke, or amaurosis fugax (monocular visual ischemic symptoms or blindness) * symptomatic bradycardia in the absence of a pacemaker * internal jugular venous thrombosis (within 3 months) * increased intracranial pressure or other contraindications to internal or external jugular venous compression * acute radiation dermatitis, unhealed surgical scar, unhealed or open wound(s), or surgical flap less than 6-8 weeks post-operative * facial or head and neck dermal metastasis * acute facial infection (e.g., facial or parotid gland abscess) * any condition in which increased venous and lymphatic return is undesirable * heart failure (acute pulmonary edema, decompensated acute heart failure) * subject is pregnant or trying to become pregnant * acute venous disease (acute thrombophlebitis, acute deep venous thrombosis, acute pulmonary embolism)

Keywords: flexitouch
40hz tacs in treating cognitive function and modulating neurophysiology of patients with alzheimer's disease

Conditions: Alzheimer Disease

Summary: gamma brain activity is crucial for cognitive function and intra-brain communication. gamma frequency stimulation via transcranial alternating current stimulation(tacs) might alleviate memory deficits on both animal models of alzheimer's disease (ad) and clinical trial. the study aims to assess the safety and efficacy of tacs on cognitive function and modulating neurophysiology in patients with ad.

gamma brain activity is crucial for cognitive function and intra-brain communication. gamma frequency stimulation via transcranial alternating current stimulation(tacs) might alleviate memory deficits on both animal models of alzheimer's disease (ad) and clinical trial. the study aims to assess the safety and efficacy of tacs on cognitive function and modulating neurophysiology in patients with ad. 40mins 10hz-tacs for daily consecutive sessions will be given.

Eligibility criteria:
inclusion criteria: * aged 60- to 90-year-old * clinical dementia rating scale (cdr) of 1 or mini-mental state examination (mmse) score of 18 to 26. * participants were allowed to maintain their anti-dementia medications without changes from at 3 months before and throughout the study. exclusion criteria: * having contraindications for tacs, e.g., implanted brain medical devices or mental in the head, having arrhythmia and with pacemaker implantation, having history of seizures, having history of intracranial neoplasms or surgery, or severe head injuries or cerebrovascular diseases * clinical depression measured by hamilton depression rating scale score equal and over 17

Keywords: alzheimer's disease tacs
accuracy of dental implant placement using two different cbct-derived templates

Conditions: Jaw, Edentulous, Partially

Summary: the main purpose of the present study is to evaluate the dental implant placement using two different cbct-derived templates and to study the related factors that affect accuracy so as to support the further clinical application of the technique. thirty patients with partial edentulous denture are recruited. they are randomized to two groups. a radiographic guide is prepared before ct/cbct scan. the ct/cbct scan dicom ﬁles are loaded in a planning program and converted into 3d computer images. a surgical template is fabricated through this virtual planning. after 6 weeks, if the implants are judged stable, the patient has the option of replacing the ﬁxed prosthesis. patients are recalled for oral hygiene maintenance and prosthetic controls every 6 months for the entire duration of the study.


Eligibility criteria:
inclusion criteria: * partial edentulism * missing more than three teeth in succession * presence of adjacent teeth * systemically healthy * good maxillomandibular relation * maximal mouth opening\>5 mm exclusion criteria: * poor oral hygiene * severe parafunctional habits, for example, bruxing and clenching * presence of clinically active periodontal disease as expressed by probing pocket depths≥4 mm in combination with bleeding on probing * maxillary sinus involvement * conditions that might lead to a possibly lowered regenerative capacity of the bone, for example, osteoporosis and paget's disease * pregnant or expecting to be pregnant * history of drug and alcohol abuse * history of systemic diseases that would contraindicate oral surgical treatment, for example, uncontrolled diabetes (defined as hba1c level \>7%) * radiotherapy in the head and neck area * on certain medications like bisphosphonates or steroids currently or within the past three months * unwillingness to return for the follow-up examination * smokers (more than20 cigarettes per day). subjects smoking \<20 cigarettes per day were requested to stop smoking before and after surgery